Skip to content

Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers

An Evidence Base Study on the Clinical Effects of Integrated Western Medicine and Traditional Chinese Medicine for Diabetic Foot Ulcer Treatment

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00393510
Enrollment
80
Registered
2006-10-27
Start date
2000-11-30
Completion date
2006-03-31
Last updated
2010-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer, Amputation

Keywords

Diabetic Foot Ulcer, Traditional Chinese Medicine

Brief summary

Chronic foot ulcers occurring among diabetic patients are difficult to heal. The frequent elderly age with co-morbidities, vascular insufficiencies, peripheral neuropathies and super imposed infections, all contribute towards the chronicity and failure of treatment. Preserving the ulcerated limb is the patients' wish. On the other hand, an infected ulcer that never heals just unnecessarily prolongs suffering. Nevertheless, patients earnestly like to try all methods of healing before accepting amputation. Objective:To determine whether a course of herbal preparation used as an adjuvant therapy for diabetic patients suffering from chronic foot ulcers may promote healing so that major leg amputation can be avoided.

Interventions

DRUGTCM

The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients. The formula consisted of 12 herbs, viz: Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae

DRUGPlacebo

Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients. The placebo was made with starch and colouring materials.

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Well Controlled diabetic state * Presence of gangrene or non-healing ulcer in diabetic patients over the foot or feet. Infection should be well controlled. * Good glycaemic control

Exclusion criteria

* Pregnant women and women at risk of conception * Patients taking digitalis glycosides * Patients with abnormal liver function tests * Patients with plasma creatinine great then 150 umol/l or unstable renal function * Poorly controlled Diabetes Mellitus * Uncontrolled infection * History of adverse reaction to herbal medicine * Unstable medical conditions * Non-compliance with regime

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Limb Salvage24 weeksThe number of successful limb rescued (without amputation).

Secondary

MeasureTime frameDescription
Tumour Necrosis Factor-alpha Levels in SerumBaseline and 4 weekThe state of inflammation at baseline and at 4 weeks after treatment. TNF-alpha are in value of serum level.
Time of Ulcer Healing24 weekTime taken for maturation of granulation to enable skin grafting.

Countries

China

Participant flow

Recruitment details

Apr 2002 to Apr 2006, Orthopaedic Department, Prince of Wales Hospital, HK Apr 2002 to Apr 2006, Orthopaedic Department, Kwong Wah Hospital, HK

Pre-assignment details

Liver Function and Renal Function test normal. Patients suffering from serious cardiac and renal deficiencies were excluded from the study because of safety measure.

Participants by arm

ArmCount
Traditional Chinese Medicine
12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
40
Placebo
Placebo was made with starch and colouring materials. Given to patient orally twice a day
40
Total80

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyPhysician Decision39

Baseline characteristics

CharacteristicTraditional Chinese MedicinePlaceboTotal
Age Continuous66.3 years
STANDARD_DEVIATION 12.6
68.5 years
STANDARD_DEVIATION 11.1
67.4 years
STANDARD_DEVIATION 11.8
Region of Enrollment
Hong Kong
40 participants40 participants80 participants
Sex: Female, Male
Female
15 Participants18 Participants33 Participants
Sex: Female, Male
Male
25 Participants22 Participants47 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 400 / 40
serious
Total, serious adverse events
0 / 400 / 40

Outcome results

Primary

Number of Participants With Limb Salvage

The number of successful limb rescued (without amputation).

Time frame: 24 weeks

ArmMeasureValue (NUMBER)
Traditional Chinese MedicineNumber of Participants With Limb Salvage37 Participants
PlaceboNumber of Participants With Limb Salvage31 Participants
Secondary

Time of Ulcer Healing

Time taken for maturation of granulation to enable skin grafting.

Time frame: 24 week

ArmMeasureValue (MEAN)Dispersion
Traditional Chinese MedicineTime of Ulcer Healing5.9 WeeksStandard Deviation 1.4
PlaceboTime of Ulcer Healing9.2 WeeksStandard Deviation 1.9
Secondary

Tumour Necrosis Factor-alpha Levels in Serum

The state of inflammation at baseline and at 4 weeks after treatment. TNF-alpha are in value of serum level.

Time frame: Baseline and 4 week

ArmMeasureGroupValue (MEAN)Dispersion
Traditional Chinese MedicineTumour Necrosis Factor-alpha Levels in SerumBaseline48 pg/mLStandard Deviation 116
Traditional Chinese MedicineTumour Necrosis Factor-alpha Levels in SerumWeek 428 pg/mLStandard Deviation 62
PlaceboTumour Necrosis Factor-alpha Levels in SerumBaseline44 pg/mLStandard Deviation 83
PlaceboTumour Necrosis Factor-alpha Levels in SerumWeek 439 pg/mLStandard Deviation 64

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026